Related Experiment Videos

Mononucleosis and hepatic failure associated with diphenylhydantoin treatment in an infant

Y H Ni1, M H Chang, M Z Wu

  • 1Department of Pediatrics, National Taiwan University Hospital, Taipei, R.O.C.

Insights

This case report details a rare instance of diphenylhydantoin-induced liver failure and a mononucleosis-like illness in a 6-month-old infant. Prompt supportive care and exchange transfusions were crucial for recovery.

Area of Science:

  • Pediatric Hepatology
  • Clinical Toxicology
  • Drug-Induced Liver Injury

Background:

  • Diphenylhydantoin (phenytoin) is an anticonvulsant medication.
  • Drug-induced liver injury and infectious mononucleosis are uncommon in children.
  • Hepatic failure following these conditions in the same individual is exceptionally rare, particularly in infants.

Observation:

  • A 6-month-old infant developed a mononucleosis-like syndrome and hepatic failure 16 days after diphenylhydantoin administration for seizure control.
  • Initial symptoms included fever, rash, hepatosplenomegaly, lymphadenopathy, and atypical lymphocytosis, mimicking infectious mononucleosis.
  • Negative heterophil antibody and viral studies (Epstein-Barr virus, cytomegalovirus, hepatitis B virus) ruled out infectious causes.

Findings:

  • The infant presented with progressive jaundice and shrinking liver size, indicative of severe hepatic dysfunction.
  • Histologic examination of liver biopsies revealed significant hepatic parenchymal loss, cholestasis, fatty change, and portal fibrosis.
  • The patient experienced stage I hepatic coma but recovered with supportive care and exchange transfusions.

Implications:

  • This case highlights the potential for diphenylhydantoin to cause severe, acute liver injury mimicking infectious mononucleosis in infants.
  • It underscores the importance of considering drug-induced etiologies in pediatric cases of hepatitis with atypical presentations.
  • Early recognition and aggressive supportive management, including exchange transfusions, may be critical for survival in severe drug-induced hepatic failure.

Related Concept Videos